Amylin Pharmaceuticals, Inc.
(Public, NASDAQ:AMLN) Watch this stockFind more results for
AMLN
Advertisement
Events
Nov 11, 2009
Credit Suisse Healthcare Conference -
Oct 26, 2009
BIOCOM Investor Conference -
Oct 20, 2009
Q3 2009 Earnings Conference Call
Oct 20, 2009
Q3 2009 Earnings Release
Sep 14, 2009
Morgan Stanley Global Healthcare Conference -
|
More events from AOL Finance »
|
Key stats and ratios
| Q3 (Sep '09) | 2008 | |
| Net profit margin | -12.62% | -37.54% |
| Operating margin | -10.61% | -35.38% |
| EBITD margin | - | -31.86% |
| Return on average assets | -6.46% | -18.09% |
| Return on average equity | -22.94% | -69.80% |
| Employees | 1,800 | - |
Address
9360 Towne Centre Drive Suite 110
San Diego, CA 92121
United States - Map
+1-858-5522200 (Phone)
+1-858-5522212 (Fax)
San Diego, CA 92121
United States - Map
+1-858-5522200 (Phone)
+1-858-5522212 (Fax)
Website links
Company website:
http://www.amylin.com/
http://www.amylin.com/
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com
Amylin Pharmaceuticals, Inc. discussed on blogs
Mike Havrilla on NVO - NovoNordisk A/S - SocialPicks
- Mike Havrilla
- SocialPicks.com: Recent Picks
- 6 hours ago
Amylin Pharmaceuticals, Inc. discussions
View all discussions »Description
Amylin Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. As of December 31, 2008, the Company was marketing two medicines to treat diabetes: BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection. In addition to its marketed products, the Company is working with Eli Lilly and Company (Lilly) and Alkermes, Inc. (Alkermes) to develop exenatide once weekly. The Company maintains a discovery research program focused on peptide and protein therapeutics.
Officers and directors
| Paulo F. Costa | Chairman of the Board | |
| Daniel M. Bradbury | President, Chief Executive Officer, Director | |
| Mark G. Foletta CPA | Chief Financial Officer, Senior Vice President - Finance | |
| Marcea Bland Lloyd | Senior Vice President - Government and Corporate Affairs, General Counsel | |
| Vincent P. Mihalik | Senior Vice President - Sales and Marketing, Chief Commercial Officer | |
| Roger Marchetti | Senior Vice President - Human Resources Information Management | |
| Orville G. Kolterman M.D. | Senior Vice President - Research and Develpoment | |
| Mark J. Gergen | Senior Vice President - Corporate Development | |
| Paul G. Marshall | Senior Vice President - Operations | |
| Lloyd A. Rowland | Vice President - Governance and Compliance, Corporate Secretary |
